For research use only. Not for therapeutic Use.
Pyrithioxin (CAT: I000411) is a neurodynamic compound that has been studied for its potential therapeutic applications in cerebral infarction patients with hemiplegia. It has been used in combination with a short period of hyperventilation (HV) as a treatment approach. The rationale behind this treatment strategy is to enhance oxygen supply to the ischemic brain region by inducing temporary hyperventilation and simultaneously administering pyrithioxin to support neurodynamic processes. By combining these approaches, it is believed that the recovery and functional outcomes in hemiplegic patients with cerebral infarction may be improved.
| Catalog Number | I000411 |
| CAS Number | 1098-97-1 |
| Molecular Formula | C16H20N2O4S2 |
| Purity | ≥95% |
| Target | Endogenous Metabolite |
| Solubility | 10mM in DMSO |
| Storage | Store at -20°C |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Pyritinol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.</span></span></span></span> |
| IUPAC Name | 5-[[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyldisulfanyl]methyl]-4-(hydroxymethyl)-2-methylpyridin-3-ol |
| InChI | InChI=1S/C16H20N2O4S2/c1-9-15(21)13(5-19)11(3-17-9)7-23-24-8-12-4-18-10(2)16(22)14(12)6-20/h3-4,19-22H,5-8H2,1-2H3 |
| InChIKey | SIXLXDIJGIWWFU-UHFFFAOYSA-N |
| SMILES | CC1=NC=C(C(=C1O)CO)CSSCC2=CN=C(C(=C2CO)O)C |
| Reference | <br /> |
